Observatory · observe first
Follow the allocation change
Matched S&P 500 members → sector → industry → sub-industry → company. Each step uses the same percentage points.
Historical time machine
Latest available · not live
20182026
1 · Sector
Weight and 12M allocation change
2 · Industry
Inside Health Care
Health Care Equipment1.52%-0.74 ppPharmaceuticals4.07%+0.69 ppBiotechnology2.04%+0.24 ppLife Sciences Tools & Services1.07%+0.17 ppHealth Care Technology0.10%+0.08 ppHealth Care Services0.41%-0.05 ppManaged Health Care0.82%-0.05 ppHealth Care Facilities0.16%-0.04 ppHealth Care Distributors0.37%-0.04 ppHealth Care Supplies0.08%-0.00 pp
3 · Sub-industry
Inside Biotechnology
Biotechnology · weight
2.04%
Industry change · 12M
+0.24 pp
Biotechnology · contribution
+0.238 pp
Company participation
100%
of industry constituents above their 6M weight average
4 · Companies driving this sub-industry
Sep 2026 · sorted by absolute contribution to 12-month change
| Company | Country | Market cap | Universe weight | 3M contribution | 12M contribution | 12M price return | Above 6M weight average |
|---|---|---|---|---|---|---|---|
| Moderna → MRNA | United States | $76.9bn | 0.129% | +0.081 pp | +0.109 pp | +645.5% | Yes |
| Amgen → AMGN | United States | $227.9bn | 0.383% | +0.043 pp | +0.079 pp | +53.5% | Yes |
| AbbVie → ABBV | United States | $462.3bn | 0.777% | +0.004 pp | -0.042 pp | +16.5% | Yes |
| Gilead Sciences → GILD | United States | $184.8bn | 0.310% | +0.038 pp | +0.035 pp | +37.6% | Yes |
| Vertex Pharmaceuticals → VRTX | United States | $132.5bn | 0.223% | +0.004 pp | +0.022 pp | +33.5% | Yes |
| Biogen → BIIB | United States | $33.3bn | 0.056% | +0.001 pp | +0.015 pp | +61.3% | Yes |
| Regeneron Pharmaceuticals → REGN | United States | $71.2bn | 0.120% | +0.018 pp | +0.014 pp | +35.6% | Yes |
| Incyte → INCY | United States | $24.2bn | 0.041% | +0.001 pp | +0.008 pp | +43.1% | Yes |
Company contributions use weights among matched S&P 500 members and add through each level without rescaling. Companies without matched shares and prices are omitted. These observations do not establish official index weights or actual fund flows.